HMG-CoA reductase inhibitors in organ transplantation

Journal of Nephrology

Volumn 10, Issue 2, 1997, Pages 68-76

  Motomura, Noboru ^a   Saito, Satoshi ^a   Foegh, Marie L ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

allograft; cholesterol; HMG CoA reductase inhibitor; immunosuppression; transplantation

Indexed keywords

COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ORGAN TRANSPLANTATION; REVIEW;

ANIMALS; CELL DIVISION; CYTOKINES; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; KILLER CELLS, NATURAL;

EID: 0031011751     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Kobashigawa JA, Katznelson S, Laks H and et al. Effect of pravastatin on outcomes after cardiac transplantation. N Eng J Med 1995; 333: 621-7.
2. Endo A, Kuroda M. Citrinin, an inhibitor of cholesterol synthesis. J Antibiot (Japan) 1976; 29: 841-3.
3. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J Antibiot (Japan) 1976; 29: 1346-8.
4. Brown AG, Smale TC, King TJ, Hasenkamp R, Thompson RH. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillum brevicompactum. J Chem Soc Perkin 1976; 1: 1165-70.
5. Endo A, Kuroda M, Tanzawa K. Competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976; 72: 323-36.
6. Kathawala FG. HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. Med Res Rev 1991; 11: 121-46.
7. Goldstein JL, Brown MS. Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. J Lipid Res 1984; 25: 1450-60.
8. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
9. Beg ZH, Stonik JA, Brewer HB Jr. In vitro and in vivo phosphorylation of rat liver 3-hydroxy-3-methylglutaryl coenzyme A reductase and its modulation by glucagon. J Biol Chem 1980; 255: 8541-5.
10. Beg ZH, Stonik JA, Brewer HB Jr. Modulation of the enzymatic activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase by multiple kinase systems involving reversible phosphorylation: a review. Metabolism 1987; 36: 900-17.
11. Roiteleman J, Simoni RD. Distinct sterol and nonsterol signals for the regulated degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Biol Chem 1992; 267: 26264-73.
12. Bradfute DL, Simoni RD. Non-sterol compounds that regulate cholesterogenesis. J Biol Chem 1994; 269: 6645-50.
13. Correl CC, Edwards PA. Mevalonic acid-dependent degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in vivo and in vitro. J Biol Chem 1994; 269: 633-8.
14. Grundy SM, Bilheimer DW. Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance. Proc Natl Acad Sci USA 1984; 81: 2538-42.
15. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. New Engl J Med 1988; 319: 24-33.
16. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992; 33: 1569-82.
17. Endo A, Hasumi K. HMG-CoA reductase inhibitors. Natural Product Reports 1993; 541-50.
18. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995; 31: 9-27.
19. Kasiske BL, Ume AJ. Persistent hyperlipidemia in renal transplant recipients. Medicine 1987; 66: 309-16.
20. Ibels S, Stewart JK, Mahony JF, Neale FC, Sheil AGR. Occlusive arterial disease in uremic and hemodialysis patients and renal transplant recipients: A study of the incidence of arterial disease and of the prevalence of risk factors implicated in the pathogenesis of arteriosclerosis. QJ Med 1977; 46: 197-214.
21. Saldanha L, Hurst K, Amend W, et al. Hyperlipidemia after renal transplantation in children. Am J Dis Child 1976; 130: 951-3.
22. Winters G; Kendall T, Radio S, et al. Posttransplant obesity and hyperlipidemia: major predictors of severity of coronary arteriopathy in failed human heart allografts. J Heart Transpl 1990; 9: 364-71.
23. Ibels L, Alfrey A, Weil R. Hyperlipidemia in adult, pediatric and diabetic renal transplant recipients. Am J Med 1978; 64: 634-42.
24. Harris KPG, Russel GI, Parvin SD, Veitch PS, Walls J. Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients. Br Med J 1986; 292: 16-8.
25. Ballantyne CM, Poder EJ, Patsch WP. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262: 53-6.
26. Rudas L, Pflugfelder P, McKenzie F, Menkis A, Novick R, Kostuk W. Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation. Am J Cardiol 1990; 66: 1135-8.
27. Kupin W, Venkat KK, Oh HK, Dienst S. Complete replacement of methylplednisolone by azathioprine in cyclosporine treated primary cadaveric renal transplant recipients. Transplant 1988; 45: 53-7.
28. Ingulli E, Tejani A, Markell M. The beneficial effects of steroid withdrawal on the lipoprotein profiles of cyclosporine treated kidney and kidney transplant recipients. Transplant 1992; 54: 868-71.
29. Gao S, Schroeder J, Hunt S, Stinson E. Retransplantation for severe accelerated coronary artery disease in heart transplant recipients. Am J Cardiol 1988; 62: 876-81.
30. Sharples L, Caine N, Mullns P, et al. Risk factor analysis for the major hazards following heart transplantation - rejection, infection, and coronary occlusive disease. Transplant 1991; 52: 244-252.
31. Foegh M, Khirabadi B, Chambers E, Amamoo S, Ramwell P. Inhibition of coronary artery transplant atherosclerosis in rabbits with angiopeptin, an octapeptide. Atheroscl 1989; 78: 229-36.
32. Koegh A, Simons L, Spratt P, et al. Hyperlipidemia after heart transplantation. J Heart Transplant 1988; 7: 171-5.
33. Stamler J, Vaughan D, Rudd A, et al. Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol 1988; 62: 1268-72.
34. Johnson MR. Transplant coronary disease: nonimmunologic risk factors. J Heart Lung Transplant 1992; 11 (Suppl): 124-31.
35. Barbir M, Ushwaha S, Hunt B, and et al. Lipoprotein (a) and accelerated coronary arteriosclerosis in cardiac transplant recipients. Lancet 1992; 340: 1500-2.
36. Valantine HA. Role of lipids in allograft vascular disease: A multicenter study of intimai thickening detected by intracoronary ultrasound. J Heart Lung Transplant 1995; 14: 234-7.
37. Markell M, Friedman E. Hyperlipidemia after organ transplantation. Am J Med 1989; 87(5): 61N-7N.
38. Cheung AK, DeVault GA, Gregory MC. A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol 1993; 3: 1884-91.
39. Hricik DE. Transplantation for nephrologists. Posttransplant hyperlipidemia: The treatment dilemma. Am J Kidney Dis 1994; 23: 766-71.
40. Castelao AM, Grinò JM, Andrés E, et al. HMG-CoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation. Transplant Proc 1993; 25: 1043-6.
41. Kainuma O, Asano T, Ochiai T, Isono K. Lipid disorders in renal transplant recipients. Transplant Proc 1992; 24: 1585-7.
42. Goldberg RB, Roth D. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76: 197A-9A.
43. Ong CS, Pollock CA, Caterson RJ, Mahony JF, Waugh DA, Ibels LS. Hyperlipidemia in renal transplant recipients: Natural hystory and response to treatment. Medicine 1994; 73: 215-23.
44. Kuo PC, Kirshenbaum JM, Gordon J, et al. Lavastatin therapy for hypercholesterolemia in cardiac transplant recipients. Am J Cardiol 1989; 64: 631-5.
45. Regazzi MB, Iacona I, Campana C, Gavazzi A, Vigano M, Perani G. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A. Transplant Proc 1994; 26: 2644-5.
46. Meiser BM, Thiery WJ, Wolf S, et al. Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. Transplant Proc 1993; 25: 2077-9.
47. Carrier M, Pelletier GB, Genest J, Cartier R, Leclerc Y, Pelletier C. Cholesterol-lowering intervention and coronary artery disease after cardiac transplantation. Ann Thorac Surg 1994; 57: 353-6.
48. Cuthbert JA, Lipsky PE. Sterol metabolsim and lymphocyte function: inhibition of endogenous sterol biosynthesis does not prevent mitogen-induced human T lymphocyte activation. J Immunol 1980; 124: 2240-6.
49. Cuthbert JA, Lipsky PE. Sterol metabolism and lymphocyte responsiveness: inhibition of endogenous sterol synthesis prevents mitogen-induced human T cell proliferation. J Immunol 1981; 126: 2093-9.
50. Herberman RB, ed. Natural cell-mediated immunity against tumors. New York, London: Academic Press, 1980.
51. Herbermann RB ed. NK cells and other natural effector cells. New York, London: Academic Press, 1982.
52. Herberman RB, Callewert DM. Mechanism of cytotoxicity by NK cells. New York, London: Academic Press, 1985.
53. Hercend T, Schmidt RE. Characteristics and uses of natural killer cells. Immunol Today 1988; 9: 291-3.
54. Cutts JL, Scallen TJ, Watson J, Bakhurst AD. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989; 139: 550-7.
55. Cutts JL, Bankhurst AD. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin. Int J Immunoph 1989; 11: 863-9.
56. McPherson R, Tsoukas C, Baines MG, et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immun 1993; 13: 439-44.
57. Rubin L, Nelson D. The soluble interleukin 2 receptor: biology, function, and clinical application. Ann Intern Med 1990; 113: 619-27.
58. Ortaldo JR, Mason L, Gerari JP, et al. Effects of natural and recombinant IL-2 on regulation of IFN gamma production and natural killer activity: Lack of involvement of the TAC antigen for these immunoregulatory events. Immunol 1984; 133: 799-83.
59. Grimm AE, Mazumder A, Zhang HZ, Rosengerg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823-41.
60. Grimm AE, Rosenberg SA. The human lymphokine activated killer cell phenomenon. Lymphokines 1984; 9: 279.
61. Linna J, Moke M, Chen HW. Isoprenoicl formation and cell-mediated immunological functions. Drugs of abuse, immunity and immunodeficiency. Friedman H, Specter S, Klein TW, eds. New York: Plenum Press 1991; 269-78.
62. Cutts JL, Bankhurst AD. Reversal of lovastatin-mediated inhibition of natural killer cell byotoxicity by interleukin 2. J Cell Physiol 1990; 145: 244-52.
63. Hardy K, Sawada T. Human γ interferon strongly up-regulates its own gene expression in peripheral blood lymphocytes. J Exp Med 1989; 170: 1021-6.
64. Halloran P, Autenried P, Ramassar V, et al. Local T cell responses induce widespread MHC expression. Evidence that IFN-γ induces its own expression in remote sites. J Immunol 1992; 148: 3837-46.
65. Amaldi I, Reigh W, Berte C, Mach B. Induction of HLA class II genes by IFN-g is transcriptional and requires a trans-acting protein. J Immunol 1989; 142: 999-1004.
66. Kramer P, Bijnen A, Kate F, et al. Recombinant leukocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; i: 989-90.
67. Vandenbroecke C, Caillat-Zucman S, Legendre C, et al. In situ expression of cytokines in renal allograft rejection. Transplant 1991; 51: 602-9.
68. Terkeltaub R, Solan J, Barry M, Santoro D, Bokoch GM. Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells. J Leukoc Biol 1994; 55: 749-55.
69. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG-CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980; 21: 505-17.
70. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
71. Chen HW. Role of cholesterol metabolism in cell growth. Fedn Proc 1984; 43: 126-30.
72. Habenicht AJ, Glomset JA, Ross R. Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem 1908; 255: 5134-40.
73. Quwsney-Huneens V, Wiley MH, Siperstein MD. Essential role for mevalonate synthesis in DNA replication. Proc Natl Acad Sci USA 1979; 76: 5056-60.
74. Quesney-Huneens V, Galick HA, Siperstein D, Erickson SK, Spencer TA, Nelson JA. The dual role of mevalonate in the cell cycle. J Biol Chem 1983; 258: 378-85.
75. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989; 57: 1167-77.
76. Schafer WR, Kim R, Sterne R, Thomer J, Kim S, Rine J. Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 1989; 245: 379-85.
77. Farnsworth CC, Wolda SL, Gelb MH, Glomset JA. Human lamin B contains a farnesylated cysteine residue. J Biol Chem 1989; 264: 20422-9.
78. Yamane HK, Farnsworth CC, Xie H, et al. Brain G protein gamma subunits contain an all-trans-geranylageranyl-cysteine methyl ester at their carboxyl termini. Proc Natl Acad Sci USA 1990; 87: 5868-72.
79. Jakobisiak M, Bruno S, Skiersky JS, Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 1991; 88: 3628-32.
80. Ross R. The pathogenesis of atherosclerosis. An update. N Engl J Med 1986; 314: 488-500.
81. Foegh M, Khirabadi B, Chambers E, Amamoo S, Ramwell P. Inhibition of coronary artery transplant atherosclerosis in rabbits with angiopeptin, an octapeptide. Atheroscl 1989; 78: 229-36.
82. Ricknbacher P, Pinto F, Lewis N, et al. Prognostic importance of intimai thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation 1995; 92: 3445-52.
83. Corsini A, Raiteri M, Soma M, Fumagalli R, Paoletti R. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacol Res 1991; 23: 173-80.
84. Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atheroscl 1993; 101: 117-25.
85. Rogler G, Lackner KJ, Schmitz G. Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro. Am J Cardiol 1995; 76: 114A-6A.
86. Scott WA. Hydrophilicity and the differential pharmacology of pravastatin. In: Wood C, ed. Lipid management: pravastatin and the differential pharmacology of HMG-CoA reductase inhibitors. Royal Society of Medicine Service, London Round Table Serie No. 16, 1989; 17.
87. Soma MR, Donetti E, Parolini C, et al. HMG-CoA reductase inibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscl Thromb 1993; 13: 571-8.
88. Gellman J, Ezekowitz MD, Sarembock IJ, et al. Effect of lovastatin on intimal hyperoplasia after balloon angioplasty: a study in an atherosclerotic hypercholesterolemic rabbit. J Am Coll Cardiol 1991; 17: 251-9.
89. Vincent TS, Wülfert E, Merler E. Inhibition of growth factor signaling pathways by lovastatin. Biochem Biophysic Res Comm 1991; 180: 1284-9.
90. Ishikawa S, Kawasumi M, Saito T. Simvastatin inhibits the cellular signaling and proliferative action of arginine vasopressin in cultured rat glomerular mesangial cells. Endocrinol 1995; 136: 1954-61.
91. O'Donnel MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993; 91: 83-7.
92. McGuire TF, Corey SJ, Sebti SM. Lovastatin inhibits platelet-derived growth factor (PDGF) stimulation of phosphatidylinositol 3-kinase activity as well as association of p85 subunit to tyrosine-phosphorylation PDGF receptor. J Biol Chem 1993; 268: 22227-30.
93. Grandaliano C, Biswas P, Choudhury GG, Abboud HE. Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 1993; 44: 503-8.
94. Carleberg M, Hjertman M, Wejde L, Larsson O. Mevalonate is essential for growth activation of human fibroblasts: evidence of a critical role of protein glycosylation in the prereplicative period. Experimental Cell Res 1994; 212: 359-66.
95. Larsson O, Blegen H. Regulatory role of mevalonate in the growth of normal and neoplastic human mammary epithelial cells. Anticancer Res 1993; 13: 1075-80.
96. Mallat A, Preaux AM, Blazejewski S, Dhumeaus D, Rosenbaum J, Mavier P. Effect of simvastatin, an inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells. Hepatology 1994; 20: 1589-94.
97. Hidaka Y, Eda T, Yonemoto M, Kamei T. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atheroscl 1992; 95: 87-94.
98. Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R. Pathogenesis of atherosclerosis and the role of 3-hydoroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 1995; 76: 21A-8A.
99. Rabinovitch M, Molossi S, Clausell N. Cytokine-mediated fibronectin production and transendothelial migration of lymphocytes in the mechanism of cardiac allograft vascular disease: efficacy of novel therapeutic approaches. J Heart Lung Transplant 1995; 14: S116-23.
100. Kreuzer J, Bader J, Jahn L, Hautmann M, Kubler W, Hodenberg EV. Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products. Atheroscl 1991; 90: 203-9.
101. Raine AE, Carter R, Mann JI, et al. Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephron Dial Transplant 1988; 3: 458-63.
102. Schorn TF, Kliem V, Bojanovski L, et al. Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients. Transplant Int 1991; 4: 92-5.
103. Kuster GM, Drexel H, Bleisch JA, et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplant 1994; 57: 1479-83.
104. Morgenstern BZ, Murphy M, Milliner DS. Interaction of lipids and cyclosporine. Transplant Proc 1994; 26: 130.
105. Carrier M, Pelletier G, Genest Jr J, Cartier R, Leclerc Y, Pelletier L. Cholesterol-lowering intervention and coronary artery disease after cardiac transplantation. Ann Thorac Surg 1994; 57: 353-6.
106. Becker D, Chamberlain B, Swank R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988; 85: 632-8.
107. Steinmüller TM, Gräf KJ, Schleicher J, et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism - a randomized trial. Transplant 1994; 58: 669-74.
108. De Groen PC, Wiesner RH, Krom RAF. Cyclosporine A-induced side effects related to a low total serum cholesterol level: an indication for a free cyclosporine A assay? Transplant Proc 1988; 20: 374-6.
109. Gardier AM, Mathé D, Guédeney X, et al. Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporin A. Therapeutic Drug Monitor 1993; 15: 274-80.
110. Ellis CN, Gorsulowski DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986; 256: 3110-6.
111. Stiller MJ, Pak GH, Kenny C, et al. Elevation of fasting serum lipids in patients treated with low dose cyclosporine for severe plaque-type psoriasis: an assessment of clinical significance when viewed as a risk factor for cardiovascular disease. J Am Acad Dermatol 1992; 27: 434-8.
112. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 1988; 260: 239-41.
113. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. New Engl J Med 1988; 318: 47-8.
114. Tobert JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. (Letter) New Engl J Med 1988; 318: 48.
115. Holdaas H, Hartmann A, Stenstrom J, Dahl KJ, Borge M, Phister P. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76: 102A-6A.
116. Li PKT, Mak TWL, Wang AYM, Lee YT, Leung CB, Lui SF, Law CWK, Lai KN. The interaction of fluvastatin and cyclosporin A in renal transplant patients. Int J Clin Pharmacol Ther 1995; 33: 246-8.
117. Arnadottir M, Eriksson L-O, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-Coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporin. Nephron 1993; 65: 410-3.
118. Kobashigawa JA, Murphy FL, Stevenson LW, et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990; 82 (Suppl): IV281-3.
119. Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transpl Proc 1993; 25: 2732-4.
120. Smith PF, Eydelloth RS, Grossman SJ, et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991; 257: 1225-35.
121. Arnadottir M, Eriksson L-O, Germeshausen JI, Thysell H. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in cyclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron 1994; 08: 57-62.
122. Yoshimura N, Oka T, Okamoto M, Ohmori Y. The effect of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992; 53: 94-9.
123. Chan MK, Varghese Z, Persaud JW, Fernando ON, Moorhead JF. The role of multiple pharmacotherapy in the pathogenesis of hyperlipidemia after renal transplantation. Clin Nephrol 1981; 15: 309-13.
124. Startzl TE, Fung J, Jordon M, Shapiro R, et al. Kidney transplantation under FK506. JAMA 1990; 264: 63-7.
125. Todo S, Fung JJ, Startzl TE, et al. Liver, kidney and thoracic organ transplantation under FK506. Ann Surg 1990; 212: 295-305.
126. Morrisett JD, Northrup SR, Gotto AM Jr, et al. Effect or FK50G and cyclosporine on plasma cholesterol levels in rabbits. Transpl Proc 1991; 23: 3185-7.
127. Baumgardner GL, Wilson GA, Tso PL, et al. Impact of serum lipids on long-term graft and patient survival after renal transplantation. Transplant 1995; 60: 1418-21.